Area of research
Infectious Diseases · Neurology
Research interest
Research interests include COVID-19 Clinical Research Studies, SARS-CoV-2 and COVID-19 Research, Long-Term Effects of COVID-19, and Asthma and respiratory diseases.
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial
Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients.
Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis
Nivolumab in Patients With Advanced or Metastatic Malignancies, Including Rare Cancers: Results of CheckMate 627, an Adaptive Basket Design Clinical Trial
Nivolumab in Patients With Advanced or Metastatic Malignancies, Including Rare Cancers: Results of CheckMate 627, an Adaptive Basket Design Clinical Trial
Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19
Simvastatin in Critically Ill Patients with Covid-19.
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial
National Institutes of Health Stroke Scale as an Outcome in Stroke Research: Value of ANCOVA Over Analyzing Change From Baseline
Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial.
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial
Hypothermia for Patients Requiring Evacuation of Subdural Hematoma: A Multicenter Randomized Clinical Trial
Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial
Colchicine for COVID-19 in adults in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19
The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design
The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design.